Abstract
There is still a need for safe, efficient and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we evaluated a vaccine candidate based on a live recombinant Newcastle disease virus (NDV) that expresses a stable version of the spike protein in infected cells as well as on the surface of the viral particle (AVX/COVID-12-HEXAPRO, also known as NDV-HXP-S). This vaccine candidate can be grown in embryonated eggs at low cost similar to influenza virus vaccines and it can also be administered intranasally, potentially to induce mucosal immunity. We evaluated this vaccine candidate in prime-boost regimens via intramuscular, intranasal, or intranasal followed by intramuscular routes in an open label non-randomized non-placebo-controlled phase I clinical trial in Mexico in 91 volunteers. The primary objective of the trial was to assess vaccine safety and the secondary objective was to determine the immunogenicity of the different vaccine regimens. In the interim analysis reported here, the vaccine was found to be safe and the higher doses tested were found to be immunogenic when given intramuscularly or intranasally followed by intramuscular administration, providing the basis for further clinical development of the vaccine candidate. The study is registered under ClinicalTrials.gov identifier NCT04871737. Funding was provided by Avimex and CONACYT.
Competing Interest Statement
PP reports financial support from the U.S. NIAID (Centers of Excellence for Influenza Research and Response 75N93021C00014, P01 AI097092-07, R01 AI145870-03). AGS reports financial support from the U.S. NIAID (Centers of Excellence for Influenza Research and Response 75N93021C00014, Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051). FK reports financial support from the U.S. NIAID (Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051, Center of Excellence for Influenza Research and Surveillance contract HHSN272201400008C), the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611, 5384), and the U.S. NCI (contract 75N91019D00024, task order 75N91020F00003); he also has received royalties (Avimex), consulting fees (Pfizer, Seqirus, Third Rock Ventures and Avimex), and payment for academic lectures during the past two years. The NDV construction administered in this study was developed by faculty members at the Icahn School of Medicine at Mount including WS, PP, AGS, and FK. Mount Sinai has filed patent applications related to SARS-CoV-2 serological assays and the NDV-based SARS-CoV-2 vaccines; the institution and its faculty inventors could benefit financially. The live vaccine used in the study was developed by members of Avimex and Avimex filed patent applications with Mount Sinai and CONACYT. M.T-R., D.S.-M., E.S.P., C.R.L-M., H.E.C-C, F.C-P., G.P-DLR and B.L-D. are named as inventors on at least one of those patent applications. The clinical study was entirely performed in Mexico. The rest of the participants are employees of their corresponding institutions.
Clinical Trial
NCT04871737
Funding Statement
The Mexican Government supports Patria via CONACYT. Its General Director and its Deputy General Director on Technological Development, Cooperation and Innovation, respectively Drs. Maria Elena Alvarez-Buylla Roces and Delia Aidee Orozco Hernandez, have been directly in charge of inter-institutional liaison, and overall facilitation of proceedings, committee evaluations, sanitary set up and supervision, as well as of trial design approvals, evaluations and progress. S.P.-R, J.J.C-M, P. S-D, Y.L-V and A.M. contributed to this study pro-bono and declare no competing interests. We additionally acknowledge the broader support from various teams within Universidad Nacional Autonoma de Mexico (UNAM) and Instituto Mexicano del Seguro Social (IMSS). From Laboratorio Avi-Mex, S. A. de C. V., we acknowledge the following people for their operative support: Bernardo Lozano Alcantara, Carlos Woolfolk Frias, Leticia Espinosa Gervasio, Rodrigo Yebra Reyes, Vanessa Escamilla Jimenez, Juan Pablo Robles Alvarez, Aviran Almazan Gutierrez, and Guadalupe Aguilar Rafael. From INER, we acknowledge the following people for their technical support: Liliana Figueroa Hernandez, Francisco Cruz Flores, Lizeth Garcia Cisneros, Claudia Ivett Hernandez Lazaro, Maria Angelica Velazquez Gonzalez, Damaris Romero Rodriguez, Jessica Romero Rodriguez, Dulce Cinthia Soriano Hernandez, Horacio Zamudio Meza, and Milton Nieto Ponce. From ProcliniQ we acknowledge the support from Enrique Camacho-Mezquita, Juan Francisco Galan-Herrera and Mariana Lopez-Martinez. The salary of PP was partially funded by NIH (Centers of Excellence for influenza Research and Response, 75N93021C00014), U.S. NIAID grant (P01 AI097092-07), U.S. NIAID grant (R01 AI145870-03), by the NIH Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051 and a grant from an anonymous philanthropist to Mount Sinai. Design and generation of reagents used in preparation for this project in the Krammer laboratory were supported by Centers of Excellence for influenza Research and Response (75N93021C00014) and Collaborative Influenza Vaccine Innovation Centers (75N93019C00051), as was the Garcia-Sastre laboratory. The authors thank Dr. Randy Albrecht for management of import/export of Newcastle disease virus vectors at the Icahn School of Medicine at Mount Sinai.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) in Mexico under number 213300410A0063/2021, after approval by the Ethics, Biosafety and Research Committees of the clinical research site Hospital Medica Sur (03-2021-CI/CEI/CB-156) in full compliance of the Mexican regulation and under the principles of the Declaration of Helsinki and Good Clinical Practice.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
